Cargando…
Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics
Osteoarthritis (OA) is a highly prevalent joint disease still lacking effective treatments. Its multifactorial etiology hampers the development of relevant preclinical models to evaluate innovative therapeutic solutions. In the last decade, the potential of Mesenchymal Stem Cell (MSC) secretome, or...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229444/ https://www.ncbi.nlm.nih.gov/pubmed/35745803 http://dx.doi.org/10.3390/pharmaceutics14061231 |
_version_ | 1784734748708438016 |
---|---|
author | Giannasi, Chiara Mangiavini, Laura Niada, Stefania Colombo, Andrea Della Morte, Elena Vismara, Valeria Ambrosanio, Andrea Savadori, Paolo Casati, Sara Peretti, Giuseppe M. Brini, Anna Teresa |
author_facet | Giannasi, Chiara Mangiavini, Laura Niada, Stefania Colombo, Andrea Della Morte, Elena Vismara, Valeria Ambrosanio, Andrea Savadori, Paolo Casati, Sara Peretti, Giuseppe M. Brini, Anna Teresa |
author_sort | Giannasi, Chiara |
collection | PubMed |
description | Osteoarthritis (OA) is a highly prevalent joint disease still lacking effective treatments. Its multifactorial etiology hampers the development of relevant preclinical models to evaluate innovative therapeutic solutions. In the last decade, the potential of Mesenchymal Stem Cell (MSC) secretome, or conditioned medium (CM), has emerged as an alternative to cell therapy. Here, we investigated the effects of the CM from adipose MSCs (ASCs), accounting for both soluble factors and extracellular vesicles, on human osteochondral explants. Biopsies, isolated from total knee replacement surgery, were cultured without additional treatment or with the CM from 10(6) ASCs, both in the absence and in the presence of 10 ng/mL TNFα. Tissue viability and several OA-related hallmarks were monitored at 1, 3 and 6 days. Specimen viability was maintained over culture. After 3 days, TNFα induced the enhancement of matrix metalloproteinase activity and glycosaminoglycan release, both efficiently counteracted by CM. The screening of inflammatory lipids, proteases and cytokines outlined interesting modulations, driving the attention to new players in the OA process. Here, we confirmed the promising beneficial action of ASC secretome in the OA context and profiled several bioactive factors involved in its progression, in the perspective of accelerating an answer to its unmet clinical needs. |
format | Online Article Text |
id | pubmed-9229444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92294442022-06-25 Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics Giannasi, Chiara Mangiavini, Laura Niada, Stefania Colombo, Andrea Della Morte, Elena Vismara, Valeria Ambrosanio, Andrea Savadori, Paolo Casati, Sara Peretti, Giuseppe M. Brini, Anna Teresa Pharmaceutics Article Osteoarthritis (OA) is a highly prevalent joint disease still lacking effective treatments. Its multifactorial etiology hampers the development of relevant preclinical models to evaluate innovative therapeutic solutions. In the last decade, the potential of Mesenchymal Stem Cell (MSC) secretome, or conditioned medium (CM), has emerged as an alternative to cell therapy. Here, we investigated the effects of the CM from adipose MSCs (ASCs), accounting for both soluble factors and extracellular vesicles, on human osteochondral explants. Biopsies, isolated from total knee replacement surgery, were cultured without additional treatment or with the CM from 10(6) ASCs, both in the absence and in the presence of 10 ng/mL TNFα. Tissue viability and several OA-related hallmarks were monitored at 1, 3 and 6 days. Specimen viability was maintained over culture. After 3 days, TNFα induced the enhancement of matrix metalloproteinase activity and glycosaminoglycan release, both efficiently counteracted by CM. The screening of inflammatory lipids, proteases and cytokines outlined interesting modulations, driving the attention to new players in the OA process. Here, we confirmed the promising beneficial action of ASC secretome in the OA context and profiled several bioactive factors involved in its progression, in the perspective of accelerating an answer to its unmet clinical needs. MDPI 2022-06-10 /pmc/articles/PMC9229444/ /pubmed/35745803 http://dx.doi.org/10.3390/pharmaceutics14061231 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Giannasi, Chiara Mangiavini, Laura Niada, Stefania Colombo, Andrea Della Morte, Elena Vismara, Valeria Ambrosanio, Andrea Savadori, Paolo Casati, Sara Peretti, Giuseppe M. Brini, Anna Teresa Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics |
title | Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics |
title_full | Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics |
title_fullStr | Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics |
title_full_unstemmed | Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics |
title_short | Human Osteochondral Explants as an Ex Vivo Model of Osteoarthritis for the Assessment of a Novel Class of Orthobiologics |
title_sort | human osteochondral explants as an ex vivo model of osteoarthritis for the assessment of a novel class of orthobiologics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229444/ https://www.ncbi.nlm.nih.gov/pubmed/35745803 http://dx.doi.org/10.3390/pharmaceutics14061231 |
work_keys_str_mv | AT giannasichiara humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT mangiavinilaura humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT niadastefania humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT colomboandrea humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT dellamorteelena humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT vismaravaleria humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT ambrosanioandrea humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT savadoripaolo humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT casatisara humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT perettigiuseppem humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics AT briniannateresa humanosteochondralexplantsasanexvivomodelofosteoarthritisfortheassessmentofanovelclassoforthobiologics |